Floatz logo

Technetium-99

Skin Squamous Cell Carcinoma

Institut de Cancérologie de LorraineUNKNOWNPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

56 Active assets in the Skin Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Prednisone
Dana-Farber Cancer Institute
Phase 4BB
Sirolimus
Dana-Farber Cancer Institute
Phase 4BB
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Regeneron Pharmaceuticals
Phase 3BB
Everolimus
Dana-Farber Cancer Institute
Phase 4BB
Indocyanine Green
Institut de Cancérologie de Lorraine
Phase 3BB

View all 50 →

Same molecule, other indications

Technetium-99 is also rated in:

anus cancerDormant
BB
Indicative · Phase 3
64 / 100
View asset →
endometrial cancerDormant
BB
Indicative · Phase 3
64 / 100
View asset →
cervical cancerDormant
B
Indicative · Phase 3
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →